Literature DB >> 33538931

Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy.

Liting Hu1, Qiulu Chen1, Zhaodong Du2, Wenying Wang1, Guiqiu Zhao1.   

Abstract

BACKGROUND: To explore the treatment efficacy of the combination of preoperative intravitreal ranibizumab (IVR) and postoperative intravitreal triamcinolone acetonide (IVTA) in patients undergoing pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR).
METHODS: A retrospective comparative study was performed on 128 eyes of 128 patients who had PDR and underwent PPV. Patients who received a single PPV were assigned to Group A. Those who received PPV with preoperative IVR were assigned to Group B. Patients in Group C underwent PPV combined preoperative IVR and postoperative IVTA. Intraoperative findings, changes in mean best-corrected visual acuity (BCVA) and postoperative adverse events, were retrospectively evaluated at 6-month follow-up.
RESULTS: The incidences of iatrogenic breaks, severe intraoperative bleeding, using long-term internal tamponade agents, recurrent vitreous hemorrhage (VH), and duration of surgery were statistically significantly less in Group B and Group C than in Group A. The postoperative BCVA was statistically significantly better in Groups B and Group C than in Group A, respectively, at 1 month after surgery. The mean 3-month postoperative visual acuity was better in Group C. The incidence of high intraocular pressure (IOP) was significantly higher in Group C at the first postoperative week. There were no statistically significant differences in the incidence of exudative retinal detachment and choroidal detachment among the three groups.
CONCLUSION: In patients undergoing PPV for PDR, preoperative IVR significantly reduced the occurrence of intraoperative and postoperative complications, and the combination of preoperative IVR and postoperative IVTA can better improve the postoperative visual outcome.

Entities:  

Keywords:  Intravitreal injection; Pars plana vitrectomy; Proliferative diabetic retinopathy; Ranibizumab; Triamcinolone acetonide

Mesh:

Substances:

Year:  2021        PMID: 33538931     DOI: 10.1007/s10792-021-01703-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  6 in total

Review 1.  Meta-analysis of the effect of perioperative injection of Lucentis on intraoperative bleeding in patients with proliferative diabetic retinopathy.

Authors:  Guoqi Guan; Jing Zang
Journal:  Eye Sci       Date:  2015-12

2.  IL-6 increases endothelial permeability in vitro.

Authors:  N Maruo; I Morita; M Shirao; S Murota
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

3.  Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.

Authors:  J Pe'er; D Shweiki; A Itin; I Hemo; H Gnessin; E Keshet
Journal:  Lab Invest       Date:  1995-06       Impact factor: 5.662

Review 4.  Inflammation and macular oedema after pars plana vitrectomy.

Authors:  Vito Romano; Martina Angi; Fabrizio Scotti; Renata del Grosso; Davide Romano; Francesco Semeraro; Paolo Vinciguerra; Ciro Costagliola; Mario R Romano
Journal:  Mediators Inflamm       Date:  2013-10-30       Impact factor: 4.711

5.  The effect of posterior sub-Tenon's capsule triamcinolone acetonide injection to that of pars plana vitrectomy for diabetic macular edema.

Authors:  Sakiko Nonomura; Toshiyuki Oshitari; Miyuki Arai; Eiju Sato; Yoko Takatsuna; Takayuki Baba; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2014-04-30

6.  Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy.

Authors:  Jinglin Cui; Hong Chen; Hang Lu; Fangtian Dong; Dongmei Wei; Yan Jiao; Steve Charles; Weikuan Gu; Lin Wang
Journal:  J Ophthalmol       Date:  2018-06-25       Impact factor: 1.909

  6 in total
  1 in total

1.  Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment.

Authors:  Xinping She; Chen Zou; Zhi Zheng
Journal:  Front Med (Lausanne)       Date:  2022-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.